Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Iliparcil is an antithrombotic compound with oral activity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 210.00 | |
5 mg | In stock | $ 540.00 | |
10 mg | In stock | $ 779.00 | |
25 mg | In stock | $ 1,180.00 | |
50 mg | In stock | $ 1,620.00 | |
100 mg | In stock | $ 2,180.00 | |
500 mg | In stock | $ 4,370.00 |
Description | Iliparcil is an antithrombotic compound with oral activity. |
In vivo | The effect of Iliparcil, a new orally active beta-D-xyloside venous antithrombotic, was studied on the thrombosis following thrombolytic therapy in rats, using a modified Umetsu model. The compound was administered by oral route prior to thrombolytic therapy, which consisted of administering a combination of heparin and urokinase (H/U) at 37.5 and 70,000 IU/kg, respectively. Time to occlusion increased from 3.9 min with saline to 10.5 min following H/U injection. When Iliparcil (30 mg/kg, oral route) was administered 4 h before H/U injection, the time to occlusion was increased by 250% compared with H/U alone (p < 0.001). Similarly, dermatan sulfate (DS), administered intravenously (3 mg/kg) 5 min before thrombus induction, also increased the time to occlusion (300% compared with H/U alone; p < 0.001). It was also shown that times to occlusion following Iliparcil or DS treatments were still increased even when heparin dosage was decreased.[1] |
Molecular Weight | 338.38 |
Formula | C16H18O6S |
CAS No. | 137214-72-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (147.76 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Iliparcil 137214-72-3 Others inhibitor inhibit